• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Increlex (mecasermin [rDNA origin] injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)


June 2014

Summary View


Post-Marketing Experience
  • General Disorders and Administrative Site Conditions: injection site reactions (e.g. erythema, pain, haematoma, haemorrhage, induration, rash, swelling).
  • Musculoskeletal and Connective Tissue Disorders: osteonecrosis/avascular necrosis (occasionally associated with slipped capital femoral epiphysis) 


February 2011

Summary View 


Known Hypersensitivity
  • Increlex should not be used by patients who are allergic to mecasermin (rhIGF-1) or any of the inactive ingredients in Increlex or who have experienced a severe hypersensitivity to Increlex


Hypersensitivity and Allergic Reactions, including Anaphylaxis
  • Allergic reactions to Increlex have been reported post-marketing. They range from localized (injection site) reactions to systemic reactions, including anaphylaxis requiring hospitalization. Parents and patients should be informed that such reactions are possible and that if a systemic allergic reaction occurs treatment should be interrupted and prompt medical attention should be sought


Post-Marketing Experience
  • Systemic hypersensitivity; anaphylaxis, generalized urticaria, angioedema, dyspnea